Doug Rice Biography and Net Worth

CFO of MiMedx Group

Mr. Rice joined MIMEDX in July 2023 as the Company’s Chief Financial Officer. He brings more than a decade of experience in the MedTech industry having served in several executive leadership positions throughout his career. Most recently, he served as the CFO of Orthofix Medical, a leading global spine and orthopedics company. Prior to Orthofix, Mr. Rice was CFO at Vision Source, held several finance leadership roles at both McAfee and Concentra, and started his career at PricewaterhouseCoopers.

Mr. Rice is a Certified Public Accountant and received his BBA with honors and his MBA from Southern Methodist University.

What is Doug Rice's net worth?: The estimated net worth of Doug Rice is at least $747,082.00 as of November 21st, 2023. Rice owns 102,200 shares of MiMedx Group stock worth more than $747,082 as of April 4th. This net worth approximation does not reflect any other investments that Rice may own. Additionally, Rice receives a salary of $470,470.00 as CFO at MiMedx Group. Learn More about Doug Rice's net worth.
How old is Doug Rice?: Rice is currently 58 years old. There are 4 older executives and no younger executives at MiMedx Group. The oldest executive at MiMedx Group is Dr. David H. Mason Jr., Chief Medical Officer, who is 77 years old. Learn More on Doug Rice's age.
What is Doug Rice's salary?: As the CFO of MiMedx Group, Inc., Rice earns $470,470.00 per year. There are 4 executives that earn more than Rice. The highest earning executive at MiMedx Group is Mr. Joseph H. Capper, CEO & Director, who commands a salary of $1,550,000.00 per year. Learn More on Doug Rice's salary.
How do I contact Doug Rice?: The corporate mailing address for Rice and other MiMedx Group executives is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. MiMedx Group can also be reached via phone at (770) 651-9100 and via email at investorrelations@mimedx.com. Learn More on Doug Rice's contact information.
Has Doug Rice been buying or selling shares of MiMedx Group?: Doug Rice has not been actively trading shares of MiMedx Group over the course of the past ninety days. Most recently, on Tuesday, November 21st, Rice Doug bought 5,000 shares of MiMedx Group stock. The stock was acquired at an average cost of $7.16 per share, with a total value of $35,800.00. Following the completion of the transaction, the chief financial officer now directly owns 102,200 shares of the company's stock, valued at $731,752. Learn More on Doug Rice's trading history.
Who are MiMedx Group's active insiders?: MiMedx Group's insider roster includes William Hulse, IV (General Counsel and Chief Administrative and Compliance Officer), Kimberly Maersk-Moller (Chief Commercial Officer), Doug Rice (CFO), and Ricci Whitlow (COO). Learn More on MiMedx Group's active insiders.
Are insiders buying or selling shares of MiMedx Group?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 144,018 shares worth more than $1,130,312.34. The most recent insider tranaction occured on March, 17th when insider Kimberly Maersk-Moller sold 1,759 shares worth more than $14,142.36. Insiders at MiMedx Group own 1.3% of the company. Learn More about insider trades at MiMedx Group.
Information on this page was last updated on 3/17/2025.

Doug Rice Insider Trading History at MiMedx Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/21/2023	Buy	5,000	$7.16	$35,800.00	102,200

Doug Rice Buying and Selling Activity at MiMedx Group

MiMedx Group Company Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Today's Range

Now: $7.31

$7.26

$7.44

50 Day Range

MA: $8.14

$7.31

$9.06

2 Week Range

Now: $7.31

$5.47

$10.14

Volume

388,827 shs

Average Volume

693,709 shs

Market Capitalization

$1.08 billion

P/E Ratio

13.29

Dividend Yield

N/A

Beta

1.97

Doug Rice Biography and Net Worth

What is Doug Rice's net worth?

How old is Doug Rice?

What is Doug Rice's salary?

How do I contact Doug Rice?

Has Doug Rice been buying or selling shares of MiMedx Group?

Who are MiMedx Group's active insiders?

Are insiders buying or selling shares of MiMedx Group?